Copyright Reports & Markets. All rights reserved.

Global PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size, Status and Forecast 2019-2025

Request for Sample of this report
Buy now

Table of Contents

    1 Report Overview

    • 1.1 Study Scope
    • 1.2 Key Market Segments
    • 1.3 Players Covered
    • 1.4 Market Analysis by Type
      • 1.4.1 Global PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size Growth Rate by Type (2014-2025)
      • 1.4.2 Temsirolimus
      • 1.4.3 Everolimus
    • 1.5 Market by Application
      • 1.5.1 Global PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Share by Application (2014-2025)
      • 1.5.2 Hospital
      • 1.5.3 Clinic
      • 1.5.4 Drug Center
      • 1.5.5 Other
    • 1.6 Study Objectives
    • 1.7 Years Considered

    2 Global Growth Trends

    • 2.1 PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size
    • 2.2 PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Growth Trends by Regions
      • 2.2.1 PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size by Regions (2014-2025)
      • 2.2.2 PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Share by Regions (2014-2019)
    • 2.3 Industry Trends
      • 2.3.1 Market Top Trends
      • 2.3.2 Market Drivers
      • 2.3.3 Market Challenges
      • 2.3.4 Porter’s Five Forces Analysis

    3 Market Share by Key Players

    • 3.1 PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size by by Players
      • 3.1.1 Global PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Revenue by by Players (2014-2019)
      • 3.1.2 Global PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Revenue Market Share by by Players (2014-2019)
      • 3.1.3 Global PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Concentration Ratio (CR5 and HHI)
    • 3.2 PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Key Players Head office and Area Served
    • 3.3 Key Players PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Product/Solution/Service
    • 3.4 Date of Enter into PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market
    • 3.5 Mergers & Acquisitions, Expansion Plans

    4 Breakdown Data by Type and Application

    • 4.1 Global PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size by Type (2014-2019)
    • 4.2 Global PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size by Application (2014-2019)

    5 United States

    • 5.1 United States PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size (2014-2019)
    • 5.2 PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Key Players in United States
    • 5.3 United States PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size by Type
    • 5.4 United States PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size by Application

    6 Europe

    • 6.1 Europe PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size (2014-2019)
    • 6.2 PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Key Players in Europe
    • 6.3 Europe PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size by Type
    • 6.4 Europe PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size by Application

    7 China

    • 7.1 China PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size (2014-2019)
    • 7.2 PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Key Players in China
    • 7.3 China PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size by Type
    • 7.4 China PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size by Application

    8 Japan

    • 8.1 Japan PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size (2014-2019)
    • 8.2 PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Key Players in Japan
    • 8.3 Japan PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size by Type
    • 8.4 Japan PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size by Application

    9 Southeast Asia

    • 9.1 Southeast Asia PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size (2014-2019)
    • 9.2 PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Key Players in Southeast Asia
    • 9.3 Southeast Asia PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size by Type
    • 9.4 Southeast Asia PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size by Application

    10 India

    • 10.1 India PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size (2014-2019)
    • 10.2 PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Key Players in India
    • 10.3 India PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size by Type
    • 10.4 India PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size by Application

    11 Central & South America

    • 11.1 Central & South America PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size (2014-2019)
    • 11.2 PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Key Players in Central & South America
    • 11.3 Central & South America PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size by Type
    • 11.4 Central & South America PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size by Application

    12 International Players Profiles

    • 12.1 Pfizer
      • 12.1.1 Pfizer Company Details
      • 12.1.2 Company Description and Business Overview
      • 12.1.3 PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Introduction
      • 12.1.4 Pfizer Revenue in PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Business (2014-2019)
      • 12.1.5 Pfizer Recent Development
    • 12.2 Gland Pharma
      • 12.2.1 Gland Pharma Company Details
      • 12.2.2 Company Description and Business Overview
      • 12.2.3 PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Introduction
      • 12.2.4 Gland Pharma Revenue in PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Business (2014-2019)
      • 12.2.5 Gland Pharma Recent Development
    • 12.3 Accord Healthcare
      • 12.3.1 Accord Healthcare Company Details
      • 12.3.2 Company Description and Business Overview
      • 12.3.3 PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Introduction
      • 12.3.4 Accord Healthcare Revenue in PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Business (2014-2019)
      • 12.3.5 Accord Healthcare Recent Development
    • 12.4 Novartis
      • 12.4.1 Novartis Company Details
      • 12.4.2 Company Description and Business Overview
      • 12.4.3 PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Introduction
      • 12.4.4 Novartis Revenue in PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Business (2014-2019)
      • 12.4.5 Novartis Recent Development
    • 12.5 Glenmark Pharmaceuticals
      • 12.5.1 Glenmark Pharmaceuticals Company Details
      • 12.5.2 Company Description and Business Overview
      • 12.5.3 PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Introduction
      • 12.5.4 Glenmark Pharmaceuticals Revenue in PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Business (2014-2019)
      • 12.5.5 Glenmark Pharmaceuticals Recent Development
    • 12.6 Cipla
      • 12.6.1 Cipla Company Details
      • 12.6.2 Company Description and Business Overview
      • 12.6.3 PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Introduction
      • 12.6.4 Cipla Revenue in PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Business (2014-2019)
      • 12.6.5 Cipla Recent Development
    • 12.7 Dr Reddy's Laboratories
      • 12.7.1 Dr Reddy's Laboratories Company Details
      • 12.7.2 Company Description and Business Overview
      • 12.7.3 PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Introduction
      • 12.7.4 Dr Reddy's Laboratories Revenue in PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Business (2014-2019)
      • 12.7.5 Dr Reddy's Laboratories Recent Development
    • 12.8 Natco Pharma
      • 12.8.1 Natco Pharma Company Details
      • 12.8.2 Company Description and Business Overview
      • 12.8.3 PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Introduction
      • 12.8.4 Natco Pharma Revenue in PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Business (2014-2019)
      • 12.8.5 Natco Pharma Recent Development
    • 12.9 Intas Pharmaceuticals
      • 12.9.1 Intas Pharmaceuticals Company Details
      • 12.9.2 Company Description and Business Overview
      • 12.9.3 PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Introduction
      • 12.9.4 Intas Pharmaceuticals Revenue in PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Business (2014-2019)
      • 12.9.5 Intas Pharmaceuticals Recent Development
    • 12.10 Panacea Biotec
      • 12.10.1 Panacea Biotec Company Details
      • 12.10.2 Company Description and Business Overview
      • 12.10.3 PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Introduction
      • 12.10.4 Panacea Biotec Revenue in PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Business (2014-2019)
      • 12.10.5 Panacea Biotec Recent Development
    • 12.11 Alkem Laboratories
    • 12.12 Biocon Pharma

    13 Market Forecast 2019-2025

    • 13.1 Market Size Forecast by Regions
    • 13.2 United States
    • 13.3 Europe
    • 13.4 China
    • 13.5 Japan
    • 13.6 Southeast Asia
    • 13.7 India
    • 13.8 Central & South America
    • 13.9 Market Size Forecast by Product (2019-2025)
    • 13.10 Market Size Forecast by Application (2019-2025)

    14 Analyst's Viewpoints/Conclusions

      15 Appendix

      • 15.1 Research Methodology
        • 15.1.1 Methodology/Research Approach
          • 15.1.1.1 Research Programs/Design
          • 15.1.1.2 Market Size Estimation
          • 12.1.1.3 Market Breakdown and Data Triangulation
        • 15.1.2 Data Source
          • 15.1.2.1 Secondary Sources
          • 15.1.2.2 Primary Sources
      • 15.2 Disclaimer

      In 2018, the global PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.

      This report focuses on the global PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer status, future forecast, growth opportunity, key market and key players. The study objectives are to present the PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer development in United States, Europe and China.

      The key players covered in this study
      Pfizer
      Gland Pharma
      Accord Healthcare
      Novartis
      Glenmark Pharmaceuticals
      Cipla
      Dr Reddy's Laboratories
      Natco Pharma
      Intas Pharmaceuticals
      Panacea Biotec
      Alkem Laboratories
      Biocon Pharma

      Market segment by Type, the product can be split into
      Temsirolimus
      Everolimus

      Market segment by Application, split into
      Hospital
      Clinic
      Drug Center
      Other

      Market segment by Regions/Countries, this report covers
      United States
      Europe
      China
      Japan
      Southeast Asia
      India
      Central & South America

      The study objectives of this report are:
      To analyze global PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer status, future forecast, growth opportunity, key market and key players.
      To present the PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer development in United States, Europe and China.
      To strategically profile the key players and comprehensively analyze their development plan and strategies.
      To define, describe and forecast the market by product type, market and key regions.

      In this study, the years considered to estimate the market size of PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025
      For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

      Buy now